THE UPLYFT COLLECTIVE
Weekly Intelligence Brief | Week of October 26, 2026
The Signal
Two governments made moves this week that could change how biotech companies are bought, funded and licensed across the U.S.-China border.
On October 16, Beijing proposed tighter controls on the transfer of certain biotechnology technologies. Six days later, the U.S. Treasury proposed restrictions on certain American investments in Chinese biotech.
The rules are different, and neither is final. But together they point to an important distinction: owning a biotechnology company or platform may become harder, while licensing the rights to use its science may remain more accessible.
China’s proposal covers certain cell and gene therapy and small-nucleic-acid technologies. It would treat licensing that does not transfer ownership more favorably than an outright transfer, although outbound licensing would still be subject to registration.
The U.S. proposal approaches the issue from the other direction. It would restrict certain investments in Chinese pharmaceutical and biotechnology businesses, including equity investments, convertible debt and joint ventures. Pure licensing is not expressly listed, although more complex licensing arrangements could still raise questions under the proposed rule.
Then look at what happened in the market.
On October 22, Gilead agreed to pay $1.275 billion for worldwide rights to HCXT-2001, an experimental treatment developed by PepStar Therapeutics. Gilead is buying the program, not PepStar itself.
Three days earlier, Merck KGaA agreed to pay approximately $1.3 billion to acquire London-based Silence Therapeutics outright.
Neither transaction was presented as a response to government policy. Each has its own strategic and clinical rationale. But put the deals beside the two regulatory proposals and a larger question emerges.
What happens when a buyer can access the science but cannot, or does not want to, own the company that created it?
That distinction could reshape dealmaking. Companies may increasingly separate the value of a drug from the value of the platform that produced it. Buyers may rely more heavily on licenses and asset purchases when ownership creates regulatory complications. And boards may need to understand not only what their technology is worth, but who is legally able to buy it.
Capital is being regulated faster than access.
That is the signal to carry into Monday. For the capability your business depends on most, could a buyer legally acquire it? If ownership became difficult, could the buyer still secure the rights it needs? And which government gets to decide?
What Smart Money Is Watching: Whether the final U.S. and Chinese rules preserve this emerging distinction between ownership and access. If they do, the structure of a biotech transaction may become nearly as important as its price.
The Capital Tape
1. Gilead bought the drug, not the company
On October 22, Gilead announced a definitive agreement to acquire an oral interleukin-23 receptor inhibitor program from PepStar Therapeutics. The centerpiece is HCXT-2001, an experimental oral treatment now in Phase 1 development.
The price is $1.275 billion in upfront cash consideration, payable at closing and subject to customary adjustments. No development milestones, sales milestones, royalties or equity investment were disclosed. Gilead expects the payment to reduce its fourth-quarter earnings per share by approximately $0.79 to $0.83. Read the Gilead release.
Here is the important part: Gilead gets the program. PepStar remains PepStar.
Gilead chose to buy worldwide rights to a specific piece of science rather than acquire the company that created it. Trade reporting places PepStar in Shanghai. BioPharm International
The companies do not connect the structure to the new U.S. or Chinese proposals, and there is no reason to assume the regulations caused the deal. The strategic lesson is broader.
A company does not always need to own the platform to capture value from what the platform produces.
That becomes more important if ownership itself gets harder.
For founders and boards, it raises a different question about exit planning. A business may have one value as an acquisition target, another as a collection of individual assets that can be licensed or sold, and a third as the platform that remains after one of those assets leaves.
Prediction, medium confidence: Over the next four to six quarters, watch for more China-origin assets to reach Western companies through licenses and purchases of product rights rather than acquisitions of the companies that created them.
Decision question: If a buyer wanted your best asset but not your company, could you sell it cleanly? And would you know what the business left behind was worth?
2. Merck KGaA chose the opposite route
Three days earlier, Merck KGaA made a very different decision.
Instead of buying one program, Merck agreed to acquire Silence Therapeutics outright for $20.00 in cash per American Depositary Share. The transaction values Silence’s equity at approximately $1.3 billion and implies an enterprise value of approximately $1.1 billion.
The offer also illustrates why headline premiums need context. Merck highlighted an 82% premium to Silence’s 30-day average price of $10.99. Silence highlighted a 130% premium to the previous Friday’s closing price. The same transaction supports both numbers because the share price immediately before the deal was well below its recent average. https://www.businesswire.com/news/home/20261019615040/en/Silence-Therapeutics-Enters-into-Agreement-to-be-Acquired-by-Merck-KGaA-Darmstadt-Germany
The clinical prize is divesiran, an experimental treatment for polycythemia vera, a blood cancer in which the body produces too many red blood cells. Merck describes divesiran as ready for Phase 3 development and potentially best-in-class.
In the companies’ reported Phase 2 results, 88% of patients responded to divesiran compared with 19% receiving placebo. Patients receiving divesiran also required fewer procedures to remove excess blood.
That gives Merck a straightforward clinical reason to pay a substantial premium. It is also buying much more than the lead drug. If the transaction closes, Merck will own Silence, its programs and its underlying RNA technology platform.
Place that next to Gilead’s deal and the contrast becomes useful.
Gilead bought access to an asset. Merck bought ownership of a company.
Neither approach is inherently better. But if governments make ownership more difficult in some jurisdictions, the ability to choose between those structures becomes strategically valuable.
Prediction, low confidence: Over the next 12 to 18 months, watch whether RNA, cell and gene therapy platforms in jurisdictions with fewer ownership restrictions begin attracting a scarcity premium. One deal cannot establish that pattern, and Silence has a strong clinical rationale of its own.
Decision question: If your company became one of a smaller number of platforms a strategic buyer could acquire outright, would your board recognize that change before a buyer did?
3. Roche shows what access can cost
On October 19, Hansoh Pharmaceutical announced a broad licensing agreement with Roche covering two preclinical antibody-drug conjugates, or ADCs, plus additional programs built on Hansoh’s platform.
ADCs are designed to deliver cancer-killing drugs more precisely by attaching them to antibodies that recognize particular targets on tumor cells.
Roche will pay Hansoh $400 million upfront and another $110 million on the first anniversary. The agreement could eventually produce more than $15 billion in development, regulatory and commercial milestone payments, plus royalties. Roche receives rights outside Greater China, while Hansoh retains the Greater China market. Read the Hansoh release.
The comparison with Roche’s earlier Hansoh deal is striking.
In October 2025, Roche paid Hansoh $80 million upfront for a Phase 1 ADC. One year later, the same buyer agreed to pay $400 million upfront for the broader relationship.
Then, four days later, Roche signed another oncology deal in Canada. It agreed to pay Zymeworks $55 million upfront for ZW209, a Phase 1 experimental cancer therapy, another $40 million when Phase 1b begins, and as much as $718 million in additional milestones. Read the Zymeworks release.
The Hansoh and Zymeworks transactions are not apples-to-apples. Hansoh’s agreement spans multiple programs and access to a platform, while Zymeworks’ covers a single clinical-stage asset.
That difference matters. But so does the size of the Hansoh check.
The older story about Chinese biopharma was that Western companies went there for less expensive innovation. The emerging story may be more interesting: Western companies may pay heavily for access to Chinese science even when they do not take ownership of the company producing it.
Prediction, medium confidence: Through 2027, watch for more cross-border licenses in which large upfront cash payments substitute for strategic equity ownership.
Decision question: In your next partnership, will the structure reflect only what the counterparty wants, or also what its government will allow it to own?
Three transactions do not make a regulatory regime. To understand whether this is a durable shift, we need to look at the rules underneath them.
The Regulatory Inflection
The question is shifting from “Can we do business there?” to “What are we allowed to own?”
If your pipeline, manufacturing network, investments or partnerships touch China, two regulatory developments deserve attention.
The first comes from Washington.
The U.S. Treasury’s proposed outbound-investment rule would restrict certain American investments connected to Chinese biotechnology and pharmaceutical activity. Comments are due December 7. Read the proposed rule.
The technical language matters, but the practical point is simpler.
Treasury is focusing on investment and ownership structures. The proposal identifies transactions such as equity acquisitions, certain convertible debt, greenfield investments, joint ventures and some limited-partner commitments.
Licensing is not expressly listed.
That does not mean every licensing deal is automatically outside the rule. A complex agreement involving equity, shared capital, governance or a joint venture could create a different legal analysis.
For senior leaders, that distinction matters because many life-sciences partnerships combine multiple elements in one transaction. A company might license a drug, make an equity investment in the developer and establish a joint development arrangement at the same time. Under the proposed framework, those pieces may no longer be treated as strategically interchangeable.
Beijing is approaching the problem from the other side of the border.
China’s Announcement No. 48 proposes tighter controls on transfers of certain cell and gene therapy and small-nucleic-acid technologies.
Here again, ownership matters. The proposal treats arrangements that transfer ownership differently from licenses that allow another party to use the technology without owning it.
China has also imposed an interim registration regime while the proposed catalogue changes are under review. That means this is not only a question for future transactions.
The U.S. and Chinese systems are different, and neither proposed restriction should be treated as final law.
But they point toward the same strategic problem.
A buyer may be able to access science it cannot easily own.
That changes diligence. The traditional questions remain: Does the technology work? Is the intellectual property defensible? What is the addressable market? What will development cost?
Now add another one: Can the eventual buyer legally own what we are building?
For boards, investors and founders, that question belongs much earlier in the process than it did a year ago.
Prediction, medium confidence: Through 2027, watch for China-linked biotech term sheets to include more explicit provisions dealing with export controls, outbound-investment restrictions, ownership and the consequences of regulatory change.
Why this matters for us: China can no longer be treated simply as a cheaper or faster source of innovation. For some transactions, it is becoming a question of what can be owned, what can only be licensed and what may require government review.
Decision question: Pick one China-linked asset, supplier or portfolio company you rely on. Does its value depend on your ability to own it, or only on your ability to access it?
That distinction between a product and the infrastructure around it also appears in another market this week: cancer care.
The Evidence Desk
A drug may help some rectal cancer patients avoid surgery. That makes the system used to identify and monitor those patients more important.
On October 19, the FDA granted accelerated approval to GSK’s Jemperli for certain adults with previously untreated, locally advanced rectal cancer.
This approval is unusual because the promise is not simply that the drug adds another treatment. For some patients, it may allow existing treatments to be removed.
In the interim analysis of AZUR-1, 154 patients received Jemperli for up to six months. After a median follow-up of more than two years, almost three-quarters had not required surgery, radiation or chemotherapy. The FDA estimates that the eligible patient population represents about 3% of locally advanced rectal cancers. Read the FDA announcement.
There is an important qualifier. These patients are not simply diagnosed with rectal cancer and given the drug. Their tumors must carry particular biological characteristics, known as mismatch repair deficiency or high microsatellite instability, identified with an FDA-authorized test.
That means the value chain begins before treatment, with identifying the right patient.
It also continues after treatment.
The published Memorial Sloan Kettering research provides a powerful signal. Among 49 patients in the rectal cancer cohort who completed treatment, all experienced a clinical complete response and chose nonoperative management. Recurrence-free survival across the study cohorts was reported at 92% at two years.
But perfect-looking averages do not eliminate individual risk. Clinicians in Italy have separately reported three patients whose disease progressed on imaging while they were still receiving treatment. Three cases cannot tell us how frequently that happens. They do show why continued monitoring matters.
When treatment disappears, the infrastructure around the patient becomes more important, not less.
A patient who does not undergo surgery still needs someone to determine whether the cancer has truly responded, someone to perform and interpret imaging and endoscopy, someone to recognize recurrence early, and someone accountable for keeping that surveillance on schedule.
That creates an opportunity beyond the drug itself.
The commercial value may sit in the diagnostic that identifies the patient, the system that combines imaging and clinical information, the registry that follows outcomes, or the care pathway that makes nonoperative management safe outside a major academic center.
Hologic made a move in an adjacent part of this market the same week, agreeing to acquire Barcelona-based Reveal Genomics. Reveal’s HER2DX test is designed to help guide treatment decisions for patients with HER2-positive breast cancer. Read the Hologic announcement.
HER2DX is not an organ-preservation product. The connection is broader: as medicine becomes better at determining who needs less treatment, the information used to make that decision becomes more valuable.
Prediction, medium confidence: Over the next 12 to 24 months, watch guideline and payer attention shift toward the systems required to monitor patients safely when established treatments such as surgery are deferred.
Decision question: If your product allows a patient to avoid a treatment, who gets paid to prove that avoiding it remains safe?
Career, Board & Capital
Career: the capability moving up in value
Marked up: people who can translate regulation into deal structure.
Business development used to be able to ask: What do we want to buy, and what are we willing to pay?
Increasingly, another question comes first: What are we legally allowed to own?
That increases the value of leaders who can sit between business development, legal, finance, regulatory affairs and strategy and turn a regulatory constraint into a workable transaction.
The expertise is not simply knowing the rule. It is understanding how to redesign the deal.
Marked down: cross-border sourcing based only on cost and speed.
Finding less expensive assets abroad is no longer enough. A cheaper molecule has limited strategic value if the eventual buyer cannot acquire the company, transfer the underlying technology or structure the investment it expected to make.
Try one exercise. Write down the three capabilities for which you are best known. For each, complete this sentence:
“This capability matters only if a regulator, payer or general counsel accepts that ______.”
If the sentence is hard to finish, someone else may control the outcome you are being paid to deliver.
Board: read what the seller kept
The headline price tells only part of the story.
PepStar is selling one program for $1.275 billion while remaining an independent company.
Hansoh is giving Roche substantial global rights while retaining Greater China.
Silence Therapeutics is taking the opposite path. If its sale closes, shareholders receive cash and Merck owns the company, its lead asset and its platform.
All three structures create value. But they leave their original owners with very different things the morning after closing.
Boards should therefore ask not only “What did we receive?” but “What do we still own when this transaction is finished?”
That question becomes particularly relevant if platforms themselves become harder to acquire.
CSL offered another leadership signal this week, naming Deborah Waterhouse its next chief executive, effective February 1, 2027. Waterhouse has led ViiV Healthcare since 2017. Read the CSL announcement.
Our read is deliberately interpretive: experience operating in a business built around partnership structures may become increasingly valuable as healthcare companies manage more complex networks of assets, alliances and ownership arrangements. CSL did not make that argument. The appointment makes it worth watching.
Capital: three ways to carry risk
Gilead, Merck and Roche are pursuing innovation, but they are taking different kinds of risk to get it.
Gilead is paying cash for a program.
Merck plans to use debt to acquire an entire company.
Roche is using partnerships that put meaningful cash upfront while leaving billions of dollars dependent on future development, regulatory and commercial milestones.
None is automatically superior. They answer different strategic questions about how much control a buyer needs, how much risk it wants today and what it is prepared to pay if the science succeeds.
Regulation now adds another variable: which form of capital is legally available in the first place?
Diligence question: In your last three transactions, did anyone document whether the asset could legally be transferred to the buyer most likely to want it?
The Syndicate Desk
We are watching platform companies whose intellectual property sits in jurisdictions where strategic buyers can still acquire ownership.
The interesting companies are not simply those with promising science. They have methods that can produce more than one asset, intellectual property that can be transferred, and value that survives even after an individual program is licensed.
A supply advantage or proprietary data moat makes that position stronger.
The investment question is changing from “Does the platform work?” to “If it works, how many buyers will actually be permitted to own it?”
Scarcity may eventually come not only from better science, but from fewer platforms being available for acquisition.
Filters met: Supply advantage and data moat.
If you are building or backing a company in this lane, write to us at hello@theuplyftcollective.com with a short description of the business and what you need.
We will route relevant opportunities to members positioned to help. Nothing shared constitutes a commitment. Please do not send confidential material without prior permission.
The Uplyft Lens: Three Moves for This Month
1. Decide whether the new rules touch you before you assume they do not
Before Treasury’s December 7 comment deadline, review any China-linked equity positions, fund commitments, convertible investments, joint ventures and licensing arrangements that also include an ownership component. If your organization also transfers Chinese biotechnology, Beijing’s November 15 comment deadline matters too.
The point is not to become your own lawyer. It is to know which assumptions in your strategy now require legal review.
2. Write one page explaining who can buy what you own
Choose the platform, process or intellectual property your business depends on most. Write down where it sits, which governments could affect a transfer, which likely buyers could acquire it, whether they could license it if ownership were unavailable, and what would remain valuable after a license or asset sale.
That is an exit-planning document, but increasingly it is also a strategy document.
3. If your product removes treatment, map what replaces it
For any product whose value proposition includes avoiding surgery, radiation, hospitalization or another major intervention, identify the people and systems responsible for confirming that avoidance remains safe.
Who qualifies the patient? Who monitors the patient? Who detects failure? Who gets paid?
Removing treatment does not remove responsibility.
What We Think Happens Next
1. Ownership and access will remain different regulatory questions
Confidence: Medium. Time horizon: Through 2027.
Both proposals place clearer attention on ownership and investment than on straightforward contractual access, although neither framework makes every licensing arrangement automatically safe.
If that distinction survives, transaction design becomes a competitive capability. Companies able to separate product rights from corporate ownership will have more options than companies built around an all-or-nothing acquisition.
What would prove us wrong: A final U.S. rule that clearly reaches pure asset licensing, or Chinese rules that erase the practical distinction between licensing and transfer of ownership.
2. Cross-border licenses will use more cash and less strategic equity
Confidence: Medium. Time horizon: Four to six quarters.
Roche paid Hansoh $80 million upfront for one ADC in October 2025. A year later, it agreed to pay $400 million upfront for a broader relationship involving multiple programs and access to Hansoh’s platform.
Those transactions are not directly comparable. But they illustrate a structure worth following: significant economic access without corporate ownership.
If equity becomes harder to use, buyers will need another way to make a deal valuable to the seller. Larger upfront payments are one obvious candidate.
What would prove us wrong: A run of major China-origin platform transactions in 2027 built around strategic equity rather than licensing economics.
3. Avoiding treatment will create a market for proving that avoidance is safe
Confidence: Medium, and the weakest of the three. Time horizon: 12 to 24 months.
Jemperli’s rectal cancer approval shows what becomes possible when a drug can eliminate surgery, radiation or chemotherapy for selected patients.
It also exposes the next problem. Someone still has to identify those patients correctly and monitor them closely enough to catch the exceptions.
That makes diagnostics, imaging, registries, clinical workflow and reimbursement part of the commercial story.
What would prove us wrong: Organ preservation expands without new clinical standards, reimbursement pathways or infrastructure emerging around structured surveillance.
What Changed Our Mind This Week
We have been reading platform transactions mainly as questions of stage and price: How mature is the technology, and what will a buyer pay for it?
Two proposals published six days apart add a prior question that scientific diligence cannot answer.
Can the platform legally change hands?
That changes the order of analysis.
Before asking what a method is worth, ask who is permitted to acquire it. Before assuming that a global buyer can take control, determine whether it can buy only product rights. Before treating licensing as safe, examine whether the structure includes equity, shared governance, capital contributions or other features that could make it look like an investment or joint venture.
The science was never the only scarce part.
The right to own it may become scarcer.
If something here is useful for a conversation you are having this week, forward it. If you are closer to one of these stories than we are, we would like to hear from you.
The Uplyft Collective
The Uplyft Collective is a private leadership ecosystem for architects of strategy in healthcare, pharma, biotech, medtech and life sciences. Take your seat at the table.
